UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success

Set To Challenge Humira In Skin Disease

Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.

UCB
• Source: UCB

UCB S.A.'s Bimzelx may have been late to get onto the psoriasis market but promising results from two late-stage hidradenitis suppurativa (HS) trials suggest that the IL-17A and IL-17F inhibitor could be the leader of the pack in treating the less-common inflammatory skin condition.

The Belgian group has released topline results from two Phase III studies of Bimzelx (bimekizumab), BE HEARD I and BE...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category